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Abstract
Background: Although evaluation of at least 12 lymph nodes (LNs) is recommended as the minimum number of
nodes required for accurate staging of colon cancer patients, there is disagreement on what constitutes an
adequate identification of such LNs.
Methods: To evaluate the minimum number of LNs for adequate staging of Stage II and III colon cancer, 490
patients were categorized into groups based on 1-6, 7-11, 12-19, and ≥ 20 LNs collected.
Results: For patients with Stage II or III disease, examination of 12 LNs was not significantly associated with
recurrence or mortality. For Stage II (HR = 0.33; 95% CI, 0.12-0.91), but not for Stage III patients (HR = 1.59; 95% CI,
0.54-4.64), examination of ≥20 LNs was associated with a reduced risk of recurrence within 2 years. However,
examination of ≥20 LNs had a 55% (Stage II, HR = 0.45; 95% CI, 0.23-0.87) and a 31% (Stage III, HR = 0.69; 95% CI,
0.38-1.26) decreased risk of mortality, respectively. For each six additional LNs examined from Stage III patients,
there was a 19% increased probability of finding a positive LN (parameter estimate = 0.18510, p < 0.0001). For
Stage II and III colon cancers, there was improved survival and a decreased risk of recurrence with an increased
number of LNs examined, regardless of the cutoff-points. Examination of ≥7o r≥12 LNs had similar outcomes, but
there were significant outcome benefits at the ≥20 cutoff-point only for Stage II patients. For Stage III patients,
examination of 6 additional LNs detected one additional positive LN.
Conclusions: Thus, the 12 LN cut-off point cannot be supported as requisite in determining adequate staging of
colon cancer based on current data. However, a minimum of 6 LNs should be examined for adequate staging of
Stage II and III colon cancer patients.
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Background
In 2010, an estimated 51,370 deaths from colorectal
cancer (CRC) are expected to have occurred, accounting
for 9% of all cancer deaths in the USA [1]. For CRC
patients, the stage of the disease predicts long-term sur-
vival and is weighed in designing treatments [2]. The
acquisition of a single positive lymph node (LN) identi-
fies Stage III patients, and the prognosis worsens as the
number of involved LNs increases [3]. These patients
a r ec h a r a c t e r i z e db yah i g hr e c u r r e n c er a t eb u tm a yb e
benefitted by adjuvant chemotherapy [4-6]. Currently,
due to conflicting results from clinical trials and popula-
tion-based studies, the role of adjuvant chemotherapy
for Stage II patients remains controversial [6]. Some
investigators, however, recommend chemotherapy for all
high-risk Stage II CRC patients, including those with
inferior LN recoveries and with peritoneal involvement,
extramural vascular invasion, tumor perforation and/or
tumor obstruction [3,7].
LN involvement is the key factor that determines the
stage and prognosis for CRCs [8]. Nevertheless, LN
positivity alone does not identify all patients with a poor
prognosis, as 20 to 40% of patients with Stage II (LN-
negative) disease die of their cancers [9,10]. In popula-
tion-based studies, the percentages of CRCs in Stages II
and III are approximately 40% and 30%, with 5-year,
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and 30-60%, respectively [11,12]. The proportion of
Stage III tumors may, however, be higher than reported
because of missing LN metastases due to inadequate
examination and resulting under-staging [13]. The sug-
gested minimum number of LNs to be examined to
stage these patients has ranged between 6 and 20
[11,14-18]. The World Congress of Gastroenterology
proposed examination of a minimum of 12 LNs for clas-
sification of tumors as Stage II [19]. In the USA, the
American Joint Committee on Cancer (AJCC), the
American Society of Clinical Oncology (ASCO) and the
College of American Pathologists (CAP), American Col-
lege of Surgeons (ACoS), Commission on Cancer (CoC),
and the National Comprehensive Cancer Network
(NCCN) have also recommended examination of at least
12 LNs to assign Stage II disease [8,20,21].
Several institutional and population-based studies
showed a survival benefit associated with increasing
numbers of LNs examined from Stage II and Stage III
CRC patients [22-25]. The origin of the database (Sur-
veillance Epidemiology and End Results, SEER, versus
NCCN) also influenced the findings of LN examination
on patient prognosis [17]. In one investigation, increased
numbers of LNs examined was associated with improve-
ments in overall survival and relapse-free survival for
Stage II but not in Stage III patients [26]. Goldstein [27]
reported that the predictive probability of finding posi-
tive LNs increased with increasing numbers of LNs
examined. In contrast, Bui et al [22] and Wong et al
[15] found no substantial increase in LN positivity with
increased numbers of examined LNs.
The recommendation by AJCC, ASCO, ACoS-CoC,
CAP, and NCCN, that examination of ≥12 LNs is suffi-
cient to stage a patient with CRC would seem to end
the debate yet anecdotal evidence suggests these recom-
mendations may not be followed. To determine how
many LNs should be examined from Stage II and III
patients with colon cancer, we evaluated a consecutive
retrospective cohort and assessed cancer-specific mortal-
ity and recurrence. We also attempted to derive a mini-
mum number of LNs needed to stage patients
appropriately and thus to minimize under-staging.
Methods
Patients
This investigation was approved by the Institutional
Review Board and Bioethics Committee of the Univer-
sity of Alabama at Birmingham (UAB). This cross-sec-
tional study was comprised of Stage II and III cancer
patients who underwent surgery for adenocarcinoma of
the colon at UAB Hospital from 1981-2002. Follow-up
ended in December, 2010. The initial study population
consisted of 566 patients. To minimize the influence of
familial/hereditary CRCs, patients < 45 years old (n =
23) were excluded, as were those with missing LN infor-
mation (n = 31). Patients who died within one week of
surgery (n = 12) and those who received neoadjuvant
chemotherapy (n = 8) were also excluded. Two were
removed due to missing tumor grade information. The
final study population was 490. In this study, only about
22% (50 of 230) of patients with Stage III disease had
received adjuvant chemotherapy for various clinical rea-
sons, and the treatment information was accounted for
in the survival analyses.
Study design
Three pathologists (CS, NCJ, and WEG) extracted the
pathologic features from pathology reports and con-
firmed by reviewing hematoxylin and eosin stained sec-
tions. CRCs were classified by the tumor-node-
metastasis (TNM) method and staged according to the
AJCC system [21]. Tumor grade was recorded as well
differentiated, moderately differentiated, poorly differen-
tiated, or unknown; no tumors were graded as undiffer-
entiated. Well and moderately differentiated tumors
were designated as “low” grade, and poorly differentiated
tumors as “high” grade [8]. Tumor size was also
obtained, and a dichotomous variable was created (≥ 5
and < 5 cm).
Demographic, clinical, and patient information regard-
ing age at the time of surgery, gender, race, surgery
date, and adjuvant chemotherapy was obtained from
medical records. Age was categorized as < 65 and ≥ 65
years. Subjects were classified as non-Hispanic African
American, or non-Hispanic Caucasian American, based
on self-identification. Patients who had adjuvant treat-
ment were categorized as “yes” if they received any 5-
fluorouracil-based chemotherapy.
Statistical analysis
A nominal categorical variable, including the current
recommendation of examining 12 LNs, was created for
the number of LNs examined based on a quartile distri-
bution. Patients were categorized by the number of LNs
examined at surgery into four groups: 1-6, 7-11, 12-19,
and ≥ 20. Survival time was calculated from the date of
surgery until either death, the termination date of the
study, or the last date of contact for patients who were
still alive at the end of the study. The primary events of
interest were colon cancer-specific death and recurrence
of disease. All reported P values were two-sided; statisti-
cal significance was defined as P < 0.05. All analyses were
performed with SAS statistical software, version 9.2.
The chi-square (c
2) statistics for categorical variables
and the t-test for continuous variables were used to
assess differences with respect to vital status, demo-
graphics along with tumor-related and clinical variables
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Meier survival curves [28] were used to compare Stage
III pN1 patients with Stage III pN2 patients for colon
cancer-specific or disease-specific survival (DSS). The
type I error rate for each test was controlled at <0.05.
For Stage II and III patients, hazard ratios (HRs) for the
bivariate association between the numbers of LNs
obtained and other covariates with death due to colon
cancers were assessed separately. From the bivariate
analysis, all variables that were associated with cancer-
specific mortality and risk of recurrence at P <0 . 2 0
were entered into the initial multivariable model con-
taining the number of LNs collected as a categorical
variable. To obtain the final model for cancer-related
mortality, the least significant variable was removed in a
step-wise manner. The association between LN exami-
nation and recurrence (at 2 and 5 years) or cancer-spe-
cific survival was obtained with the overall survival as
well as 5-year cancer-specific survival and risk of recur-
rence. The final multivariable models for survival and
recurrence were used separately to obtain HRs for the
association between the numbers of LNs examined and
cancer-specific survival and risk of recurrence. These
multivariable, stage-specific models were adjusted for
age, race, gender, treatment, and tumor location, size,
and grade to assess the cancer-specific survival or risk
of recurrence. For LN-positivep a t i e n t s ,t h ea s s o c i a t i o n
between the number of LNs examined (continuous) and
the number of positive LNs found was assessed. For
stage III (LN-positive) patients, linear regression was
used to estimate the association between the number of
LNs examined (continuous) as a predictor for the num-
ber of positive LNs. The linear regression equation to
obtain parameter estimation was: Y=b0 + b1X1+b2X2
+ E(Y = number of positive lymph nodes, b1 = the num-
ber of lymph nodes examined, and b2 =c o v a r i a t e ,X1 =
the value of number of lymph nodes examined, X2 = is
the value of a covariate, and E = error term). For Stage
III patients, the probability of a tumor being classified as
pN2 (≥ 4 positive LNs) was obtained for the four cate-
gories of LNs.
Results
The characteristics of the study population and their
cancers
The median age of the study population was 68 (45 to
99 years). As shown in Table 1, Stage III patients were
younger (< 65: n = 98, 42.6%; P = 0.02) than Stage II
patients (n = 85, 32.7%). There were more patients with
larger tumors in Stage II (≥ 5 cm: n = 144, 55.4%; P =
0.04) than in Stage III (n = 106, 46.1%). In accordance
with current treatment recommendations, more Stage
III patients received adjuvant chemotherapy (n = 50,
21.7%; P < 0.0001).
There was a significant difference between Stage II
and Stage III according to the vital status (P < 0.0001).
As compared to Stage II patients (n = 77, 29.6%), more
Stage III patients died due to colon cancer (n = 123,
53.5%). There were more recurrences within two years
among Stage III patients compared to Stage II patients
(P = 0.048). However, there was no stage difference
according to the number of LNs extracted relative to
gender, race, or tumor grade.
The association between the number of LNs collected
and colon cancer recurrence
Compared to patients with <12 LNs identified, collection of
≥12 LNs was not significantly associated with recurrence at
2 or 5 years, as determined by multivariate analyses of
Stage II and III colon cancers (Table 2). For Stage II
patients, the higher categories of LNs obtained were asso-
ciated with a decreased risk of recurrence, although only
the ≥ 20 category approached significance, with a 67%
decreased risk of recurrence within 2 years (HR = 0.33;
95% CI, 0.12-0.91). The stage-wise association between
LNs harvested and 5-year recurrence, however, was not
statistically significant (Table 2). For Stage III patients,
there was no relationship between increasing numbers of
LNs examined with cancer recurrence (Table 2).
The rates of recurrence decreased with increases in
the number of LNs removed for both Stage II (R =
-0.692, p = 0.0004) (Figure 1A) and III (R = -0.774, p <
0.0001) (Figure 1B) patients; however, for Stage II and
III colon cancer patients, there was no statistically sig-
nificant difference in the rates of recurrence after the
collection of 6 - 19 LNs (Table 2).
The association between the number of LNs obtained
and disease-specific survival
As noted for recurrence at 2 years, multivariate analyses
showed that collection of 12 LNs as the cutoff was not sig-
nificantly associated with disease-specific survival (DSS)
for Stage II (HR = 0.61; 95% CI, 0.37 - 1.00) or Stage III
(HR = 0.97; 95% CI, 0.64 - 1.46) (Table 3) patients. Multi-
variate analyses according to the categorical variables,
showed, however, that, compared to the category of 1-6
LN retrieved, the three higher categories (7-11, 12-19, ≥
20) exhibited an improved 5-year and overall DSS. The ≥
20 category had significantly better survival than those
with <6 LNs in Stage II (5 years-HR = 0.42; 95% CI, 0.20 -
0.90; overall- HR = 0.45; 95% CI, 0.23 - 0.87) but not for
Stage III (5 years-HR = 0.74; 95% CI, 0.39 - 1.40; overall-
HR = 0.69; 95% CI, 0.38 - 1.26) (Table 3).
The association between the number of LNs retrieved
with LN positivity in Stage III colon cancer
The number of positive LNs examined was obtained
for Stage III patients. As determined by linear
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resulted in a 19% increased probability of collecting a
positive LN (parameter estimate = 0.1851, p < 0.0001).
Therefore, collection of six additional LNs resulted
in identification of one additional positive LN (1/
0.1851 = 5.4).
The association between the number of LNs obtained
with the probability of identifying pN2 tumors in stage III
colon cancer
Logistic regression was utilized to obtain the predictive
probability (PP) of obtaining ≥ 4 positive LNs (pN2 des-
ignation) according to the number of LNs obtained,
Table 1 Characteristics of the study population (N = 490)
StageII (n = 260, 53.1%) Stage III (n = 230, 46.9%)
Variable n (%) n (%) P value
Age (years) 0.024
< 65 85 32.7 98 42.6
≥ 65 175 67.3 132 57.4
Sex 0.959
Male 134 51.5 118 51.3
Female 126 48.5 112 48.7
Race 0.202
Caucasian Americans 165 63.5 133 57.8
African Americans 95 36.5 97 42.2
Tumor grade 0.380
Low 216 83.1 184 80.0
High 44 16.9 46 20.0
Tumor location 0.521
Distal 100 38.5 95 41.3
Proximal 160 61.5 135 58.7
Tumor size (cm) 0.040
< 5 116 44.6 124 53.9
≥ 5 144 55.4 106 46.1
Adjuvant chemotherapy < 0.0001
No 237 91.2 180 78.3
Yes 23 8.8 50 21.7
Status < 0.0001
Alive 89 34.2 59 25.6
Death due to colon cancer 77 29.6 123 53.5
Death due to other causes 94 36.2 48 20.9
Recurrence (years) 0.048
No 209 80.4 163 70.9
≤ 2 35 13.5 47 20.4
> 2 16 6.1 20 8.7
Number of LNs harvested 0.615
1-6 55 21.2 38 16.5
7-11 63 24.2 57 24.8
12-19 75 28.8 73 31.7
≥ 20 67 25.8 62 27.0
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6 LNs collected had an 18% (PP = 0.184) chance of hav-
ing a pN2 tumor. Patients with 7-11 and 12-19 nodes
obtained had probabilities of 37% (PP = 0.370) and 38%
(PP = 0.382), respectively. Patients with ≥ 20 LNs
extracted had a 43% chance (PP = 0.433) of having a
pN2 tumor (data not shown). Analysis of Stage III CRCs
based on the status of nodal involvement (pN1 versus
pN2) demonstrated no significant difference in the rate
of recurrence within 2 (HR = 2.43, 95% CI, 1.37 - 4.32)
or 5 years (HR = 2.06, 95% CI, 1.26 - 3.39) (data not
shown); however, patients with pN2 colon cancers had a
lower survival than pN1 patients (log-rank p = 0.012)
(Figure 2).
Discussion
For both Stage II and III colon cancer patients,
increased numbers of LNs retrieved were associated
with reduced risk of recurrence and improved cancer-
specific survival. Identification of ≥20 LNs correlated
significantly with reduced risk of recurrence and
mortality of Stage II but not Stage III patients. For Stage
III patients, collection of six additional LNs resulted in
identification of one additional positive LN, and the
probability of finding patients with pN2 nodal stage
increased with increasing numbers of LNs examined.
LN involvement determines the pathologic stage and
forms the basis for selection of patients for adjuvant
therapy [8]. Although Stage II disease, which has a rela-
tively good prognosis, is characterized by the absence of
LN involvement, about one third of these patients
experience recurrences, due either to missed micro-
metastases or to aberrant drainage of LNs beyond the
field of resection, leading to under-staging [3,9,12].
Furthermore, for Stage III patients, inadequate LN
recognition is associated with a poorer prognosis
Table 2 Multivariate analyses of numbers of LNs
obtained and recurrence of colon cancer at 2 and 5 years
Adjusted
a HRs (95% C.I.)
LNs extracted Stage II Stage III
Recurrence in 2 years
Current guideline
< 12 ref ref
≥ 12 0.62 (0.32, 1.22) 1.27 (0.67, 2.40)
Quartiles
1-6 ref ref
7-11 0.72 (0.29, 1.79) 1.49 (0.52, 4.26)
12-19 0.63 (0.26, 1.52) 1.54 (0.55, 4.34)
≥ 20 0.33 (0.12, 0.91) 1.59 (0.54, 4.64)
Recurrence in 5 years
Current guideline
< 12 ref ref
≥ 12 0.67 (0.37, 1.24) 1.16 (0.67, 1.99)
Quartiles
1-6 ref ref
7-11 0.64 (0.27, 1.51) 1.24 (0.53, 2.91)
12-19 0.62 (0.26, 1.52) 1.23 (0.53, 2.84)
≥ 20 0.47 (0.20, 1.11) 1.44 (0.61, 3.42)
HR, hazard ratio; CI, confidence interval.
aAdjusted for age, race, and tumor grade. The Stage III model was also
adjusted for chemotherapy status and the number of positive LNs.
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Figure 1 Overall risk of recurrence in Stage II (A) and III (B)
colon cancers. Linear regression analysis of data from Stage II & III
colon cancer patients demonstrates a decreasing risk of recurrence
with increasing numbers of LNs identified. Note that Stage II & III
patients with < 6 LNs harvested had the highest risk of recurrence;
however, collection of 6 to 19 LNs resulted in a similar risk of
recurrence. Collection of >20 LNs conferred a significantly reduced
risk of recurrence.
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effect on prognosis [29-31]. Thus, diligent searches for
LNs are needed for accurate assessment of nodal status
and for correct assignment of stage.
The AJCC, ASCO, CAP, ACoS-CoC, and NCCN have
recommended that a minimum of 12 LNs be examined
in order to rule out metastases via the lymphatic system
to nodal tissues [8,20,21]. This recommendation, how-
ever, is not widely practiced. Only 58% of those in the
SEER database had ≥12 LNs harvested [17], and the
NCCN database review documented a 60% failure rate
in achieving resection of 12 LNs among various USA
hospitals [18]. Various minimum numbers of LNs har-
vested (range: 6 to 40) from colon resections, have been
suggested for adequate staging of colon cancer patients
[15,22,26,32].
An increased LN examination confers a survival bene-
fit, especially for stage II disease [14,27,32-34]. In the
current investigation, however, examination of 12 LNs
showed no significant survival benefit. By disease stage,
there was a 55% and 31% reduced risk of cancer-specific
mortality for Stage II and III patients, respectively, for
those with ≥ 20 LNs examined. The 5-year survival of
Stage II cases was 54.9%, whereas the survival of those
who had ≥ 9 LNs examined after surgery was 79.9%
Table 3 Bivariate and multivariate associations of number of lymph nodes harvested with 5-year and overall colon
cancer-specific survival
Un-adjusted HRs (95% C.I.) Adjusted
a HRs (95% C.I.)
LNs extracted Stage II Stage III Stage II Stage III
5 Years DSS
Current guideline
< 12 ref ref ref ref
≥ 12 0.65 (0.40, 1.07) 1.13 (0.77, 1.64) 0.61 (0.37, 1.00) 0.97 (0.64, 1.46)
Quartiles
1-6 ref ref ref ref
7-11 0.93 (0.60, 1.43) 1.64 (0.91, 2.94) 0.85 (0.43, 1.67) 0.87 (0.41, 1.85)
12-19 0.89 (0.58, 1.34) 0.97 (0.55, 1.71) 0.68 (0.35, 1.32) 0.97 (0.55, 1.70)
≥ 20 0.54 (0.35, 0.83) 1.02 (0.57, 1.82) 0.42 (0.20, 0.90) 0.74 (0.39, 1.40)
Overall DSS
Current guideline
< 12 ref ref ref ref
≥ 12 0.69 (0.44, 1.07) 1.09 (0.76, 1.56) 0.65 (0.42, 1.02) 0.95 (0.64, 1.40)
Quartiles
1-6 ref ref ref ref
7-11 0.69 (0.37, 1.28) 0.84 (0.48, 1.48) 0.75 (0.40, 1.40) 0.83 (0.47, 1.47)
12-19 0.68 (0.38, 1.24) 1.01 (0.60, 1.70) 0.67 (0.37, 1.22) 0.94 (0.56, 1.59)
≥ 20 0.45 (0.23, 0.87) 0.94 (0.55, 1.61) 0.45 (0.23, 0.87) 0.69 (0.38, 1.26)
DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval.
aAdjusted for age, race, and tumor grade. The Stage III model was also adjusted for chemotherapy status and the number of positive LNs.





























Figure 2 Survival in pN1 vs. pN2 Stage III colon cancers. Kaplan-
Meier survival curves demonstrating significant difference in disease-
specific survival between Stage III patient groups of pN1 and pN2.
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8 LNs examined was similar to that for Stage III patients
(51.8%). Sixteen of 17 studies of Stage II and 4 of 6 stu-
dies of Stage III showed improved patient survival with
increased number of LNs examined [16]. In contrast, for
Stage III patients, the number of LNs examined did not
serve as a prognosticator [36]. The demonstration of
increased mortality associated with the examination of ≤
6 LNs, compared to > 6, especially in Stage II patients,
is in concordance with other reports [16,24,27].
With tumor recurrence as the outcome for Stage II
patients, all higher categories of LN collections showed
a decreased risk, but only the ≥ 20 category approached
significance, with a 67% decreased risk of recurrence
within 2 years after surgery. In contrast, for Stage III
patients, there was no relationship between increasing
numbers of LNs examined with colon cancer recur-
rence. A low risk of recurrence for patients with ≥ 14
L N se x a m i n e dc o m p a r e dt os m a l l e rn u m b e r sw a s
reported earlier [32]. There was a significant difference
in recurrence with the number of LNs examined.
Further, for pN1 and pN2 patients, disease-free survival
improved as more LNs were removed, but there was no
such association for node-negative patients. The impact
of LN ratio (ratio of tumor-infiltrated nodes to total
number of harvested LNs) on 3-year, disease-free survi-
val was more prominent for patients with > 12 LNs
examined [37].
In general, examination of an increased number of
LNs results in greater chances of identifying LN metas-
tases, thus minimizing under-staging [14,27,32-34]. In
our investigation of patients with Stage III disease, for
each additional LN collected, there was 19% increased
probability of finding a positive LN. Thus, collection of
six additional LNs resulted in finding one additional
positive LN. In a mathematical model, the predictive
probability of identifying single LN metastases was 0.25
if 12 LNs were examined and 0.46 if 18 LNs were exam-
ined [27]. Since the probability of LN positivity increases
as the number examined increases, there is no minimum
number that reliably stages all patients [27,33]. Higher
LN counts, however, do not always correlate with
increased rates of nodal positivity [22].
The accuracy of staging depends on multiple factors,
including those that are modifiable (e.g., surgeon and
pathologist) and un-modifiable (e.g., age, obesity, and
socioeconomic status of the patient and anatomic loca-
tion of the tumor) [16,38,39]. Pathologists encounter
challenges in adequate LN retrieval. In Stage II colon
cancer, the age of the patient, tumor size, specimen
length, use of a structured pathology template, and aca-
demic status of the hospital are predictors of LN collec-
tion [40]. Up to 70% of metastases are found in LNs
that are < 5 mm in diameter and hence likely to be
missed on routine visualization or palpation [41].
Another challenge for pathologists relates to micro-
metastases or isolated tumor cells that are missed in
routine histological examinations. Although immunohis-
tochemistry and polymerase chain reactions to identify
cytokeratin and carcinoembryonic antigen [42] have
been used to highlight malignant cells, the prognostic
significance of LNs containing such micro-metastases is
uncertain [35]. Targeted LN examination by mapping of
the most proximal LN (sentinel LN) improves the sta-
ging accuracy for colon cancer [43,44]. In LN mapping,
however, there are inconsistencies [45-47] that may be
attributable to inadequate standardization, training, and
interpretation of micro-metastases and to skip metas-
tases [43,48].
Survival in colon cancer is influenced by the presence
of positive LNs and by the total number of positive LNs
[32]. For Stage III tumors, the AJCC sub-classifies nodal
staging into pN1 and pN2, based on the presence of ≥4
positive LNs [21]. In our analysis, the probability of hav-
ing pN2 patients increased from 18% to 43% as the
number of LNs examined increased from < 7 to ≥ 20.
Similarly, there was increased disease-free survival as
more LNs were examined from pN1 and pN2 patients
[32]. The probability of missing a positive LN was
29.7%, 20.0%, and 13.6% when five, eight, and twelve
LNs, respectively, were examined [49]. For node-positive
patients, increased numbers of LN examination corre-
lated with a lower LN ratio, which was associated with a
better prognosis [37,50]. Although most of these investi-
gations involved large sample sizes, the cutoff values dif-
fered; thus, further investigations were warranted.
Conclusions
In summary, the mandatory 12 LNs examination recom-
mended by different agencies (AJCC, ASCO, NCCN,
etc.) did not demonstrateas i g n i f i c a n t l yl o wr i s ko f
recurrence or survival benefit. Moreover, collection of
≥7o r≥12 LNs had similar outcomes. Hence, a mini-
mum of 6 LNs should be examined for adequate staging
of Stage II and III colon cancer patients. Collection of ≥
20 LNs, however, was associated with reduced risk of
recurrence and improved survival for Stage II but not
for Stage III colon cancer patients. Also, there is an
improved survival with increased numbers of LNs har-
vested from Stage II and Stage III patients regardless of
the cutoff points used. For Stage III tumors, every six
additional LNs harvested resulted in identification of a
positive LN. The probability of finding a pN2 patient
increased with increasing numbers of LNs collected.
Thus, to minimize stage misclassification and to aid in
therapeutic decisions for colon cancer patients, the sur-
geons should perform more extensive lymphadenec-
tomies and the pathologists should screen the surgical
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ble. Furthermore, the findings from institutional studies,
like ours, relate to the population of the serving area
they represent. Thus, there may be geographic differ-
ences which can be addressed in future studies and
minimized when one follows uniform treatment and
pathology protocols.
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